Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$1.24M-$1.24MN/M vs Q2 2021 EPS Diluted-$1.01-$1.01N/M vs Q2 2021 Operating Income-$730,261N/M Operating Cash Flowderived-$554,777N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
ended Feb 28, 2022 · filed Apr 12, 2022 · 43 d after period end